Patents by Inventor Angelica Loskog

Angelica Loskog has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Medical agents and uses thereof
    Patent number: 10973875
    Abstract: The invention provides a novel compounds derived from CD154, but without the intracellular domain. Notably, the invention provides TMZ-CD154 and a method to treat diseases in which the novel molecule TMZ-CD154 is used. In particular, TMZ-CD154 is used to modify the immune responses in patients with immune related diseases such as cancer and infectious disease. The invention also relates to a method to activate cells with the TMZ-CD154 in vitro either prior to using the activated cells for therapy or for diagnostic purposes.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: April 13, 2021
    Assignee: LOKON PHARMA AB
    Inventor: Angelica Loskog
  • NEW MEDICAL AGENTS AND USES THEREOF
    Publication number: 20170189480
    Abstract: The invention provides a novel compounds derived from CD154, but without the intracellular domain. Notably, the invention provides TMZ-CD154 and a method to treat diseases in which the novel molecule TMZ-CD154 is used. In particular, TMZ-CD154 is used to modify the immune responses in patients with immune related diseases such as cancer and infectious disease. The invention also relates to a method to activate cells with the TMZ-CD154 in vitro either prior to using the activated cells for therapy or for diagnostic purposes.
    Type: Application
    Filed: April 7, 2015
    Publication date: July 6, 2017
    Applicant: LOKON PHARMA AB
    Inventor: Angelica Loskog
  • Medical methods and agents for use therein
    Patent number: 8685640
    Abstract: The present invention provides an immunomodulatory agent for use in the local treatment of tumors, wherein the treatment comprises patient-specific optimization of the dose of the immunomodulatory agent to identify the maximum therapeutic dose that does not induce an increase in the number of local regulatory T cells (Treg cells) in the patient The invention further provides methods for the local treatment of tumors as well as methods for optimising treatments for the same.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: April 1, 2014
    Assignee: Alligator Bioscience AB
    Inventors: Thomas Tötterman, Linda Sandin, Angelica Loskog, Sara Mangsbo, Peter Ellmark
  • MEDICAL METHODS AND AGENTS FOR USE THEREIN
    Publication number: 20130004483
    Abstract: The present invention provides an immunomodulatory agent for use in the local treatment of tumours, wherein the treatment comprises patient-specific optimisation of the dose of the immunomodulatory agent to identify the maximum therapeutic dose that does not induce an increase in the number of local regulatory T cells (Treg cells) in the patient The invention further provides methods for the local treatment of tumours as well as methods for optimising treatments for the same
    Type: Application
    Filed: November 17, 2010
    Publication date: January 3, 2013
    Applicant: Alligator Bioscience AB
    Inventors: Thomas Tötterman, Linda Sandin, Angelica Loskog, Sara Mangsbo, Peter Ellmark